RxDoctor Payments Data

Qingwei Yan, MD

Urology · Oakland, CANPI 1003995648

Payments from drug & device makers

$13,508in general payments, 2019–2025

Across 366 payments — averaging $36.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$3K
  • Astellas Pharma US Inc$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$859
  • Dendreon Pharmaceuticals LLC$539
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$1001%
  • Speaking & faculty fees$2,00015%
  • Travel & lodging$1,2769%
  • Food & beverage$9,48270%
  • Education$6505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,508 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$472,810
Medicare patients
742
Services billed
7,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide60$833,096
MyrbetriqMirabegron772$806,223
ErleadaApalutamide33$482,841
GemtesaVibegron120$149,994
Tamsulosin Hcl857$16,194
Mirabegron ErMirabegron18$9,371
Finasteride540$7,555
Dutasteride76$4,091
Desmopressin Acetate52$3,774
Estradiol45$2,893
Alfuzosin Hcl ErAlfuzosin Hcl75$1,871
Doxazosin Mesylate87$1,668
Testosterone25$1,611
Bicalutamide37$1,133
Terazosin Hcl38$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$2,181$1,639,319832 claims
Johnson & JohnsonErleada$1,014$482,84133 claims
Sumitomo Pharma America, Inc.Gemtesa$859$149,994120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.

Other urology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →